p53 is present at low levels in unstressed cells. Numerous cellular insults, including DNA damage and microtubule disruption, elevate p53 protein levels. Phosphorylation of p53 is proposed to be important for p53 stabilization and activation after genotoxic stress; however, p53 phosphorylation after microtubule disruption has not been analysed. The goal of the current study was to determine if p53 phosphorylation increases after microtubule disruption, and if so, to identify speci®c p53 residues necessary for microtubule inhibitor-induced phosphorylation. Two dimensional gel analyses demonstrated that the number of p53 phosphoforms in cells increased after treatment with microtubule inhibitors (MTIs) and that the pattern of p53 phosphorylation was distinct from that observed after DNA damage. p53 phosphorylation also varied in a MTI-dependent manner, as Taxol and Vincristine induced more p53 phospho-forms than nocodazole. Further, MTI treatment increased phosphorylation of p53 on serine-15 in epithelial tumor cells. In contrast, serine-15 phosphorylation of p53 did not increase in MTI-treated primary cultures of human ®broblasts. Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol-and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53. Taken together, the results of this study demonstrate that distinct p53 phospho-forms are induced by MTI treatment as compared to DNA damage and that p53 phosphorylation is mediated in a MTI-and cell-speci®c manner. Oncogene (2001) 20, 113 ± 124.
Introduction
The p53 tumor suppressor protein is present at low levels in unstressed cells, likely due to MDM2 binding and targeting p53 for ubiquitin-mediated degradation (Kubbutat et al., 1997; Haupt et al., 1997) . However, cellular insults, such as DNA damage, oncogenic stimuli, or microtubule disruption, elevate p53 protein levels. While upstream p53 signaling pathways induced by genotoxic stress and oncogenic stimuli have been identi®ed, pathways that mediate p53 activation after microtubule disruption have not been elucidated. Cells lacking p53-dependent signaling undergo endoreduplication and become polyploid after microtubule inhibitor (MTI) treatment (Cross et al., 1995; Di Leonardo et al., 1997; Khan and Wahl, 1998; Lanni and Jacks, 1998; Stewart et al., 1999a) . Further, tumor cells with defective p53-mediated G1/S checkpoint function are sensitized to MTI treatment in vivo (Stewart et al., 1999b) . Since drugs that alter microtubule dynamics are widely used chemotherapeutic agents, identifying the signaling pathways involved in p53 activation after microtubule disruption may have important therapeutic implications.
After genotoxic stress, phosphorylation of p53 may be important for p53 stabilization. Numerous cellular kinases mediate phosphorylation of p53 after ionizing radiation (IR) and ultraviolet radiation (UV). Several members of the phosphoinositide-3 kinase (PI-3K) family can directly phosphorylate p53 on amino terminal residues after both IR and UV treatment, including DNA-activated protein kinase (DNA-PK), ataxia-telangiectasia mutated (ATM) kinase and ATMrelated kinase (ATR) (Lees-Miller et al., 1992; Canman et al., 1998; Banin et al., 1998; Tibbetts et al., 1999; Hall-Jackson et al., 1999) . DNA-PK is activated by DNA double-strand breaks and phosphorylates p53 on Ser-15 and Ser-37 in vitro (Lees-Miller et al., 1992) . ATM is also activated by DNA double-strand breaks and phosphorylates p53 on Ser-15 in vitro (Canman and Lim, 1998; Canman et al., 1998) . ATM function is defective in patients with ataxia-telangiectasia (AT), a disorder in which patients have increased sensitivity to radiation and are highly cancer prone (Lavin and Shiloh, 1996) . Cells from AT patients have delayed p53 stabilization and signi®cantly diminished Ser-15 phosphorylation after IR exposure (Siliciano et al., 1997; Shieh et al., 1997; Canman et al., 1998) . ATR phosphorylates p53 on both Ser-15 and Ser-37 in vitro and overexpression of a catalytically inactive ATR reduces Ser-15 phosphorylation at late times after IR (Tibbetts et al., 1999; Hall-Jackson et al., 1999) . DNA-PK and ATM also phosphorylate MDM2 after DNA damage, preventing formation of the p53-MDM2 complex (Mayo et al., 1997; Khosravi et al., 1999) .
Thus, post-translational regulation of the p53-MDM2 interaction likely occurs by modi®cations on both proteins.
ATM-dependent signaling induced by DNA damage also results in the activation of the Chk1 and Chk2 kinases (Matsuoka et al., 1998; Sanchez et al., 1997; Furnari et al., 1997) . Chk1-and Chk2-mediated phosphorylation of p53 on Ser-20 may be important for p53 stabilization after DNA damage (Hirao et al., 2000; Shieh et al., 2000; Chehab et al., 2000) . Chk2 phosphorylates p53 on Ser-20 in vitro and this phosphorylation dissociates p53-MDM2 complexes (Chehab et al., 2000) . Additionally, Chk27/7 embryonic stem cells fail to maintain IR-induced cell cycle arrest, a phenotype similar to that of p537/7 cells (Hirao et al., 2000) . Further, wild type (wt) Chk1 phosphorylates p53 on Ser-20 in vitro and overexpression of Chk1 increases levels of p53 protein in cells (Shieh et al., 2000) . Since mutation of Ser-20 to alanine abrogates p53 stabilization after both IR and UV exposure (Chehab et al., 1999) , Chk1 and Chk2 may play an important role in DNA damage-induced p53 activation.
Several other cellular kinases mediate phosphorylation of p53 after genotoxic stress. The p38 stressactivated kinase phosphorylates p53 on Ser-33 and Ser-46 afer UV radiation but not IR (Bulavin et al., 1999) . Inhibition of p38 kinase activity or mutation of Ser-33 and Ser-46 to alanines reduced p53-mediated apoptosis and decreased sensitivity to UV radiation, suggesting p38 plays an important role in p53 signaling after UV exposure (Bulavin et al., 1999) . Casein kinase I (CKI) phosphorylates murine p53 on Ser-4, Ser-6, and Ser-9 in vitro (Milne et al., 1992; Knippschild et al., 1997) . CKI also phosphorylates human p53 on Thr-18 in vitro, a modi®cation that required prior Ser-15 phosphorylation (Dumaz et al., 1999; Sakaguchi et al., 2000) . However, further studies are necessary to determine if CKI phosphorylates p53 on Thr-18 after DNA damage in vivo.
Numerous kinases and phosphatases regulate the phosphorylation of p53 on carboxy terminal sites. Both casein kinase II and the double stranded RNAactivated protein kinase PKR phosphorylate p53 on Ser-392, a modi®cation proposed to control p53-mediated transactivation (Hupp et al., 1992; Hall et al., 1996; Cuddihy et al., 1999) . Protein kinase C mediates phosphorylation of three carboxy terminal serine residues of p53: Ser-371, Ser-376, and Ser-378 (Baudier et al., 1992) . Of note, Ser-376 and Ser-378 are constitutively phosphorylated in cells, and Ser-376 is dephosphorylated in response to DNA damage in an ATM-dependent manner (Waterman et al., 1998) . Dephosphorylation of Ser-376 results in enhanced binding of 14-3-3 proteins to p53 and mediates increased sequence-speci®c DNA binding by p53 (Waterman et al., 1998) . Finally, phosphorylation of Ser-315 by Cdk2 and Cdc2, as well as dephosphorylation by Cdc14, may in¯uence the nuclear localization of p53 and regulate p53 binding to a subset of p5t3 consensus DNA binding sites (Wang and Prives, 1995; Hecker et al., 1996; Li et al., 2000) . Several p53 upstream signaling pathways induced by genotoxic stress and oncogenic stimuli (Sherr and Weber, 2000) have been determined in recent years; however, the mechanism(s) by which p53 is activated after microtubule disruption has not been identi®ed. The goal of the current study was to determine if p53 phosphorylation increases after microtubule disruption, and if so, to identify speci®c p53 residues necessary for MTI-induced phosphorylation. The results demonstrate that distinct p53 phospho-forms are induced by MTI treatment as compared to DNA damage. Phosphorylation of p53 on Ser-15 increased in epithelial tumor cells but not in non-transformed ®broblasts after microtubule disruption. Further, multiple p53 amino terminal residues, including Ser-15 and Thr-18, were required for Taxol-induced phosphorylation of ectopically expressed p53 phospho-mutant proteins.
Results

Taxol and vincristine treatments induce multiple p53 phospho-forms
To analyse p53 phosphorylation after microtubule disruption, protein lysates were prepared from control and Taxol-treated HCT116 cells, and p53 was analysed by two dimensional (2D) gel electrophoresis. Taxol treatment of HCT116 cells resulted in a signi®cant increase in the number and amount of phospho-forms detected by 2D analysis as compared to those observed in a control lysate (Figure 1a) . We analysed 1 mg of control lysates as compared to 150 mg of protein lysate from Taxol-treated cells to ensure that the additional p53 phospho-forms observed in the treated samples were a re¯ection of stress-induced changes and not merely higher p53 protein levels. The faster migrating phospho-form labeled S represents an internal standard provided by the admixture of a recombinant carboxy terminal truncated human p53 protein (amino acids 1 ± 353) (Szak and Pietenpol, 1999) to the IEF sample buer (Figure 1a ). To con®rm that the multiple p53 species detected by 2D analysis were a result of phosphorylation, an aliquot of the Taxol-treated HCT116 lysate was incubated with potato acid phosphatase prior to 2D analysis. Phosphatase treatment collapsed the phosphoforms to a single species of protein labeled P 0 (Figure 1a) . Sequential phospho-forms are indicated as P 1 and P 2 ; phospho-forms beyond P 2 were not assigned. Of note, each of the various p53 phospho-forms (P 0 , P 1 , P 2 , etc.) likely comprise a mixture of phosphorylated p53 species with identical mass/charge ratios.
To compare MTI-induced p53 phosphorylation to that induced by genotoxic stress, protein lysates were prepared from HCT116 cells treated with MTIs (Taxol, Vincristine, nocodazole) and DNA damaging agents (IR, ADR, UV) and evaluated by 2D gel electrophoresis. All treatments except nocodazole induced an increase in the relative number of p53 phospho-forms beyond those present in the control lysate, as well as a p53 phosphorylation after microtubule disruption ZA Stewart et al distinct p53 phosphorylation pattern (Figure 1b) . The dierent patterns of p53 phospho-forms induced by Taxol, Vincristine, and nocodazole treatments also suggest distinct signaling pathways are activated by these MTIs (Figure 1b ).
Serine-15 phosphorylation of p53 is increased in MTI-treated tumor cells
After exposure of cells to genotoxic agents, p53 phosphorylation on Ser-15 increases and is proposed to play a role in p53 stabilization (Canman et al., 1998; Banin et al., 1998; Craig et al., 1999) . To determine if microtubule disruption induces phosphorylation of p53 on Ser-15, protein lysates from HCT116 cells treated with Taxol and nocodazole were examined by Western analysis using an antibody speci®c to p53 phosphorylated at Ser-15. Samples were also evaluated to assess total p53 protein levels and changes in the protein levels of the p53 downstream targets MDM2 and p21. For comparison, lysates from IR-and ADR-treated HCT116 cells were also analysed. After treatment of HCT116 cells with Taxol or nocodazole, an increase in total p53 protein levels was detectable by 12 h (Figure 2a , PAb1801). The increase in p53 after nocodazole treatment was accompanied by elevations in MDM2 and p21 protein levels. In contrast, after Taxol treatment, the elevation in p53 protein was accompanied by a decrease in MDM2 protein levels ( Figure 2a ). Ser-15 phosphorylation of p53 also increased above control levels in nocodazole-and Taxol-treated cells. Fluoroimager analyses were performed to quantify the PAb1801 and the a-Ser-15 p53 chemiluminescent signals to determine the fold increase of total p53 and Ser-15 phosphorylated p53 relative to control for each treatment; these numbers appear below the PAb1801 and the a-Ser-15 p53 panels in Figure 2a . Treatment with both MTIs increased p53 Ser-15 phosphorylation for all timepoints evaluated ( Figure  2a ). For example, after 12 h Taxol treatment, there was a 3.6-fold increase in Ser-15 phosphorylated p53 as compared to a 1.6-fold increase in total p53 protein ( Figure 2a ). After IR and ADR treatments, the levels of total p53 protein and Ser-15 phosphorylated p53 increased for all timepoints examined, consistent with previous studies (Canman et al., 1998; Gao et al., 1999) , and was accompanied by elevations in MDM2 and p21 protein levels ( Figure  2a) .
To verify the results obtained in the HCT116 cells, total p53 and Ser-15 phosphorylated p53 levels were analysed in the RKO human colon carcinoma cell line after treatment (Figure 2b ). Similar to HCT116 cells, MTIs and DNA damaging agents induced an elevation in Ser-15 phosphorylated p53 greater than the elevation in total p53 protein for all timepoints (Figure 2b ). For example, after 48 h nocodazole treatment, there was a 18.2-fold increase in Ser-15 phosphorylated p53 as compared to a 8.5-fold increase in total p53 protein ( Figure 2b ). Comparable increases in Ser-15 phosphorylated p53 and total p53 were observed after 48 h Taxol treatment, as the increase in Ser-15 phosphorylated p53 was a fold greater than that observed for total p53 protein levels ( Figure 2b ). Like the HCT116 cells, the increase in p53 after nocodazole, IR, and ADR treatments was accompanied by elevations in Figure 1 Taxol and Vincristine treatments induce multiple p53 phospho-forms. (a) Lysates from control and Taxol-treated (100 nM) HCT116 cells were analysed by 2D gel electrophoresis. To verify that the p53 forms were a result of phosphorylation, parallel lysates prepared from Taxol-treated cells were treated with potato acid phosphatase (PAP) prior to 2D gel analysis. S denotes the migration of the internal standard protein, a truncated form of human p53. P 0 indicates the migration of unphosphorylated p53, while P 1 and P 2 denote various phosphoforms of p53. The various p53 phospho-forms (P 0 , P 1 , P 2 ) likely comprise a mixture of phosphorylated p53 species with identical mass/charge ratios. (b) Lysates from control and cells treated with Taxol (100 nM), Vincristine (100 nM), nocodazole (83 nM), IR (10 Gy), ADR (350 nM), or UV (100 mJ) for the indicated times were analysed by 2D gel electrophoresis. Samples were evaluated with the PAb1801 antibody. Results are representative of three independent experiments MDM2 and p21 protein levels, while MDM2 protein levels decreased after Taxol treatment in the RKO cells (Figure 2b ).
To determine if the decrease in MDM2 protein levels after Taxol treatment was mediated by transcriptional regulation of the MDM2 promoter, Northern analyses were performed on mRNA isolated from nocodazoleand Taxol-treated HCT116 cells. Both nocodazole and Taxol treatment resulted in increased MDM2 and p21 mRNA levels after 24 and 48 h of treatment ( Figure  2c) . Thus, the reduction in MDM2 protein levels after Taxol treatment was not a consequence of a decrease in MDM2 mRNA.
Increased serine-15 phosphorylation of p53 after MTI treatment occurs in a cell-specific manner ATM is required for p53 stabilization and Ser-15 phosphorylation after IR, as cells from AT patients have signi®cantly reduced p53 protein levels and Ser-15 phosphorylation as compared to normal cells after IR (Siliciano et al., 1997; Shieh et al., 1997; Canman et al., 1998; Banin et al., 1998) . To determine if ATM plays a role in MTI-induced elevation of Ser-15 phosphorylation, ATM-de®cient ®broblasts (AT-1) were treated with Taxol or nocodazole and the relative levels of Ser-15 phosphorylated p53 determined by Western. MTI treatment did not increase Ser-15 phosphorylation of p53 in the AT-1 ®broblasts after adjustment for the increase in total p53 protein ( Figure 3a) . However, p53 was not signi®cantly phosphorylated on Ser-15 after MTI treatment in normal human dermal ®broblasts (NHDFs) (Figure  3b ), suggesting MTIs induce distinct signaling pathways in ®broblasts that do not increase Ser-15 phosphorylation. Of note, the MTI-mediated increases in total p53 were not signi®cantly reduced in AT-1 cells as compared to the fold increases observed in NHDFs, suggesting that MTI-induced stabilization of p53 is not ATM-dependent (Figure 3) . Further, similar p53 phospho-forms were observed in lysates prepared from Taxol-treated NHDF and AT-1 ®broblasts (data not shown).
NHDFs and AT-1 cells were also treated with IR and ADR to verify that Ser-15 phosphorylation of p53 could occur in NHDFs (Figure 3 ). IR and ADR treatments increased Ser-15 phosphorylated p53 in both NHDFs and AT-1 cells; however, the IR and ADR-induced elevations in total p53 protein levels and Ser-15 phosphorylated p53 were greater in NHDFs as compared to AT-1 ®broblasts (Figure 3 ).
Analysis of p53 amino terminus phospho-mutant proteins after treatment of cells with MTIs, IR, and ADR
To further investigate p53 phosphorylation after microtubule disruption, p53-de®cient H1299 cells were transfected with a panel of expression vectors encoding phosphorylation-site mutant p53 proteins, the cells were treated with Taxol or nocodazole, and the ectopically expressed p53 proteins were examined by 2D gel electrophoresis. The proteins analysed in this study include the following point mutants in which serine or threonine were mutated to alanine: Ser-15 (S15A), Thr-18 (T18A), Ser-20 (S20A), Ser-37 (S37A) (Ashcroft et al., 1999) . A Thr-18 point mutant in which threonine was mutated to aspartic acid (T18D) (Ashcroft et al., 1999 ) and a double mutant in which Ser-15 and Thr-18 (S15A/T18A) (Blattner et al., 1999) were altered to alanine were also used in these experiments. In addition, a p53 mutant (N/C-Term) in which a majority of the previously described p53 amino terminal and carboxy terminal phosphorylation sites were mutated to alanine was examined; this protein contained alanine substitutions at residues 6, 9, 15, 18, 20, 33, 37, 315, 371, 376, 378 and 392 (Ashcroft et al., 1999) . Expression of each p53 mutant protein was veri®ed by Western (data not shown).
To determine if ectopically expressed wt p53 was phosphorylated after Taxol treatment, wt p53 was transiently expressed in H1299 cells in the presence or absence of Taxol and evaluated by 2D analysis. A similar number of wt p53 phospho-forms were observed in Taxol-treated H1299 cells as compared to endogenous p53 in Taxol-treated HCT116 cells (Figures 1a and 4a) . Further, p53 protein isolated from Taxol-treated H1299 cells had signi®cantly more phospho-forms than the untreated wt p53 control, verifying that ectopically expressed p53 was phosphorylated after MTI treatment (Figure 4a) . Alignment by the internal standard protein allowed assignment of P 1 , P 2 , and P 3 for the ectopically expressed p53 proteins (Figure 4a, S) . Initial 2D analysis of each mutant protein was performed in the absence of cellular stress. All the mutants, with the exception of T18D, had a reduced number of p53 phospho-forms as compared to wt p53 (Figure 4b) . A signi®cant fraction of the T18A mutant protein was present as the P 1 phospho-form as compared to wt p53 or any other point mutant (Figure 4b ). In addition, the N/C-Term p53 mutant migrated at predominantly the P 0 form, a ®nding consistent with the removal of the majority of To determine if mutation of speci®c phosphoresidues aected the MTI-induced phosphorylation of p53, each of the mutant proteins was expressed in H1299 cells, the cells were treated with Taxol or nocodazole for 24 h, and the ectopically expressed p53 proteins were examined by 2D analysis. Taxol treatment did not signi®cantly increase phosphorylation of the N/C-Term mutant, as the majority of the protein remained as the P 0 form, suggesting Taxolinduced phosphorylation was dependent on the mutated p53 phospho-residues (Figure 5a ). All of the amino terminal point mutants examined had reduced p53 phosphorylation as compared to wt p53 after Taxol treatment (Figure 5a ). For example, Taxol Figure 3 ATM-de®cient cells have a delayed increase in p53 protein levels after Taxol treatment. Western analysis of MDM2, total p53 (PAb1801), Ser-15 phosphorylated p53 (a-Ser-15), p21, and actin protein levels in AT-1 (a) or NHDF (b) cells after treatment with Taxol (100 nM), nocodazole (83 nM), IR (10 Gy), and ADR (350 nM). Results are representative of three independent experiments p53 phosphorylation after microtubule disruption ZA Stewart et al treatment did not increase the number of S15A mutant phospho-forms beyond those observed in the control wt p53. This result was consistent with the detection of Ser-15 phosphorylation in HCT116 and RKO cells after Taxol treatment (Figure 2a,b) . The T18A mutant had the most signi®cant reduction in phosphorylation of all the p53 single point mutants evaluated with the majority of the protein in the P 1 form and a lesser amount at P 2 (Figure 5a ). Further, replacement of Thr-18 with aspartic acid (T18D) partially rescued p53 phosphorylation (Figure 5a ). Taken together, these data suggest that Taxol-induced phosphorylation of p53 requires multiple amino terminal residues that function either as direct phosphorylation sites or as recognition sequences for kinases that phosphorylate other p53 residues. Similar to Taxol treatment, the nocodazole-treated N/C-Term mutant remained predominantly in the P 1 form (Figure 5b) . In contrast to Taxol treatment, mutation of individual p53 amino terminal residues did not signi®cantly impair nocodazole-mediated phosphorylation, suggesting that distinct signaling pathways are activated by these two MTIs (Figure 5b ). For example, nocodazole-mediated phosphorylation of the T18A mutant protein resembled that observed with wt p53, with the majority of the protein in the P 2 or greater phosphorylated forms. This result is signi®-cantly dierent from that observed after Taxol treatment, as the majority of the T18A protein was in the P 1 phospho-form after Taxol exposure ( Figure  5a,b) . Thus, similar to the 2D data obtained with endogenous p53 in HCT116 cells (Figure 1b) , analysis of ectopically expressed p53 point mutant proteins suggests that Taxol and nocodazole induce distinct p53 phosphorylation patterns.
Analysis of IR-and ADR-induced phosphorylation of the p53 mutant proteins demonstrated that the S37A mutant had the most signi®cant reduction in p53 phosphorylation as compared to wt p53, suggesting that phosphorylation of Ser-37 is important for subsequent phosphorylation of p53 after genotoxic stress (Figure 5c,d) . Like Taxol and nocodazole treatment, IR and ADR treatment did not signi®cantly increase the p53 phospho-forms detected in the N/CTerm mutant (Figure 5c,d) . After IR or ADR exposure, the majority of the T18A mutant was present as P 2 or greater phospho-forms (Figure 5c,d) , in contrast to Taxol treatment, in which a signi®cant fraction of the T18A mutant protein was present as the P 1 phospho-form (Figure 5a ).
To further investigate p53 phosphorylation after MTI treatment, the S15A/T18A double mutant was analysed by 2D electrophoresis. Similar to the untreated T18A mutant, the control S15A/T18A mutant protein had a signi®cantly higher level of the P 1 phospho-form as compared to wt p53 or any other Figure 4 Taxol treatment induces phosphorylation of ectopically expressed p53 on multiple sites. (a) Lysates from control and Taxol-treated (100 nM) H1299 cells transfected with wt p53 were analysed by 2D gel electrophoresis. The P 0 and the P 1 and P 2 phospho-forms in the ectopically expressed p53 proteins were assigned by alignment with the internal standard protein (S). (b) Lysates from untreated H1299 cells transfected with wt p53 or the indicated p53 point mutants were analysed by 2D gel electrophoresis. P 0 and the P 1 and P 2 phospho-forms were assigned by alignment with the internal standard protein. The various p53 phospho-forms (P 0 , P 1 , P 2 ) likely comprise a mixture of phosphorylated p53 species with identical mass/charge ratios. Results are representative of three independent experiments Oncogene p53 phosphorylation after microtubule disruption ZA Stewart et al (350 nM) were analysed by 2D gel electrophoresis. P 0 and the P 1 and P 2 phospho-forms were assigned by alignment with the internal standard protein. The various p53 phospho-forms (P 0 , P 1 , P 2 ) likely comprise a mixture of phosphorylated p53 species with identical mass/charge ratios. Results are representative of two independent experiments Figure 6 Mutation of Ser-15 and Thr-18 results in reduced phosphorylation of p53 after treatment with MTIs and genotoxic agents. Lysates from H1299 cells transfected with either the S15A/T18A p53 double point mutant (a) or the T18A p53 point mutant (b) and treated with Taxol (100 nM), nocodazole (83 nM), IR (10 Gy), and ADR (350 nM) were analysed by 2D gel electrophoresis. The various p53 phospho-forms (P 0 , P 1 , P 2 ) likely comprise a mixture of phosphorylated p53 species with identical mass/charge ratios. Results are representative of two independent experiments p53 phosphorylation after microtubule disruption ZA Stewart et al individual point mutant protein (Figures 4b and 6a) . In contrast to the single point mutant proteins evaluated, the S15A/T18A mutant protein had a signi®cant reduction in phosphorylation after treatment with either MTIs or genotoxic agents, as the majority of the protein migrated as the P 1 and P 2 phospho-forms (Figure 6a ). This ®nding diers from the phosphorylation patterns observed with either the S15A or T18A point mutant proteins. For example, the S15A mutant protein had reduced phosphorylation after Taxol, nocodazole, IR and ADR treatment as compared to wt p53, but all treatments induced phosphorylation beyond the P 2 phospho-form ( Figure  5 ). Similarly, while the T18A mutant protein had a reduction in phospho-forms after Taxol treatment, it was phosphorylated beyond the P 2 phospho-form after nocodazole, IR, or ADR treatment (Figure 6b ). These results suggest that under all conditions examined, phosphorylation of Ser-15 or Thr-18 is required for phosphorylation of subsequent sites.
Discussion
Recent studies have identi®ed signaling pathways that regulate p53 activation after DNA damage or oncogene activation; however, the mechanism(s) by which p53 is activated after microtubule disruption has not been elucidated. The goal of the current study was to analyse p53 phosphorylation after microtubule disruption and to identify speci®c p53 residues necessary for MTI-induced phosphorylation. Two dimensional gel electrophoresis of p53 from MTItreated HCT116 cells demonstrated that p53 phosphorylation increased after microtubule disruption and that Vincristine and Taxol induced signi®cantly more phospho-forms than nocodazole. Further, mutation of p53 amino terminal phosphorylation sites signi®cantly impaired Taxol-induced phosphorylation of p53, while nocodazole-mediated phosphorylation was minimally reduced. These data suggest that dierent upstream signaling pathways are activated by speci®c MTIs and result in distinct phosphorylation patterns of p53. Further, 2D analysis of ectopically expressed p53 phospho-mutant proteins demonstrated that Thr-18 is a critical residue for subsequent phosphorylation of p53 after Taxol treatment, while Ser-37 is an important residue for subsequent p53 phosphorylation after genotoxic stress. It remains to be determined if Thr-18 and Ser-37 function as direct phosphorylation sites or as part of recognition sequences for kinases that phosphorylate other p53 residues. In HCT116 and RKO cells, MDM2 mRNA and protein levels increased after nocodazole treatment, whereas after Taxol treatment, MDM2 protein levels decreased, despite an increase in MDM2 mRNA levels. In contrast, both MTIs induced an elevation in p21 mRNA and protein levels. Several groups have reported dierential upregulation of p21 and MDM2 after p53 activation; however, there has been concordant regulation of the target gene mRNA and protein levels. For example, camptothecin induced p53-mediated elevation in p21 mRNA and protein levels and failed to increase MDM2 mRNA or protein levels (Ashcroft et al., 2000) . Similarly, after exposure to high dose UV, p21 mRNA and protein levels rapidly increased, while MDM2 mRNA and protein levels decreased (Wu and Levine, 1997) . Thus, the protein levels of p21 and MDM2 after speci®c stresses is typically modulated by p53 transcriptional regulation of the respective promoters. The ®nding that Taxol treatment induces transcriptional upregulation of MDM2 but not an elevation in steady state MDM2 protein levels, suggests the presence of an alternative mechanism that decreases MDM2 protein levels without aecting p53 protein levels.
Several signi®cant ®ndings in this study resulted from experiments using the Ser-15 p53 phospho-speci®c antibody. For example, in contrast to the elevation in Ser-15 phosphorylated p53 observed in MTI-treated HCT116 and RKO epithelial tumor cells, the elevation in Ser-15 phosphorylated p53 in Taxol-treated NHDFs and ATM-de®cient ®broblasts was only re¯ective of the increase in total p53 protein. These results suggest that the non-transformed ®broblasts and transformed epithelial tumor cells examined in this study induce distinct signaling pathways after microtubule disruption, resulting in dierential phosphorylation of p53.
Adding a further layer of complexity to interpretation of the biological consequences of p53 phosphorylation are recent studies indicating that there is interplay between the phospho-sites, such that phosphorylation on one residue may require phosphorylation on a prior site. For example, Bulavin et al. (1999) observed that substitution of alanine at Ser-33 completely blocked UV-induced phosphorylation at Ser-37 but did not decrease phosphorylation at Ser-15. In contrast, the S33A/S46A double mutant abrogated UV-induced phosphorylation of Ser-37, and signi®-cantly reduced phosphorylation at Ser-15 (Bulavin et al., 1999) . This previous ®nding suggests that either the presence of Ser-33 and Ser-46 residues, or their ability to be phosphorylated, is important for amino terminal phosphorylation of p53 after cells are exposed to UV light. Similarly, Sakaguchi et al. (2000) and Dumaz et al. (1999) recently reported that IR-induced phosphorylation of p53 on Thr-18 required prior phosphorylation on Ser-15. The results from the current study are consistent with these latter studies, as the S15A/T18A double mutant was not signi®cantly phosphorylated after microtubule disruption or genotoxic stress, in contrast to the T18A single point mutant protein that was phosphorylated after nocodazole, IR and ADR treatments.
Currently, a major challenge in the p53 ®eld is linking biochemical modi®cations of the protein with biological eects. The studies cited above and the results presented in the current study illustrate the need for higher resolution techniques that will allow analysis of p53 after cellular stress. Mass spectrometric analysis of the p53 protein was recently used by Abraham et al. (2000) to identify p53 sites that are covalently modi®ed in vivo, either constitutively or in response to IR. By identifying speci®c post-translational modi®cations after cellular stress, the biochemical activity of dierentially modi®ed p53 molecules at speci®c promoters can begin to be evaluated. For example, co-analysis of p53 by mass spectroscopy and in vivo promoter-trapping (Murphy et al., 1999; Szak and Pietenpol, submitted) after a speci®c cellular stress may allow important insight to the p53 post-translational modi®cations required for a biological endpoint.
Since drugs that alter microtubule dynamics such as Taxol are important anticancer agents, identifying the post-translational modi®cations that mediate elevation of p53 protein levels after microtubule disruption in tumor cells may have important therapeutic implications. The results from this study indicate that MTI treatment of epithelial tumor cells results in distinct patterns of phosphorylation as compared to genotoxic stress. However, we cannot rule out that microtubule disruption leads to DNA alterations in cells. Thus, the p53 phospho-forms observed may be due to DNA damage signaling pathways distinct from those induced by the genotoxic agents examined in this study. The elucidation of kinases that regulate phosphorylation of p53 after MTI treatment may ultimately identify novel targets for chemotherapeutic intervention. For example, loss of p53 function in tumor cells can enhance cellular sensitivity to MTIs (Stewart et al., 1999b) . Thus, the development of compounds which inhibit kinases that phosphorylate and activate p53 after microtubule disruption may enhance therapeutic ecacy when these compounds are combined with MTIs to treat tumors with intact p53 signaling pathways.
Materials and methods
Cell culture and treatment
The HCT116 and RKO human colorectal carcinoma cell lines were obtained from American Type Culture Collection (ATCC) and were maintained in monolayer culture in McCoys 5A modi®ed medium (Gibco ± BRL) supplemented with 10% fetal bovine serum (FBS; Gemini Bio-Products, Inc.), and 1% penicillin/streptomycin (Sigma). H1299 human large cell lung carcinoma cells (ATCC) have a partial homozygous deletion of the p53 gene, and p53 protein expression is not detectable (Mitsudomi et al., 1992) . H1299 cells were maintained in monolayer culture in F-12 medium (Sigma) supplemented with 10% FBS and 1% penicillin/streptomycin. Normal human dermal ®broblasts (NHDFs) (Vanderbilt University Research Center) were maintained in monolayer culture in Dulbecco's Modi®ed Eagle Medium-Hi Glucose (Gibco ± BRL) supplemented with 10% FBS and 1% penicillin/streptomycin. The GM02052C (AT-1) ®broblast cell line derived from AT patients (Coriell Institute for Medical Research) was maintained in monolayer culture in Minimum Essential Medium with Earle's salts (Hyclone) supplemented with 15% FBS, 1% penicillin/ streptomycin, 2 mM non-essential amino acids (Hyclone), 50 mg/ml insulin-transferrin-selenium A (Boehringer Mannheim), 1 mM MEM amino acids (Gibco ± BRL), and MEM vitamins (Gibco ± BRL). All cells were grown at 378C with 5% CO 2 in a humidi®ed incubator.
When indicated, cells were treated with nocodazole (Sigma), paclitaxel (Taxol; Sigma), or Vincristine (Eli Lilly and Co.) diluted in dimethyl sulfoxide and added directly to cell media. Cells were also treated with adriamycin (ADR) (Gensia Sicor Inc.) diluted in media, ionizing radiation (IR), or ultraviolet radiation (UV) when indicated. IR was delivered at room temperature with a 137 Cs irradiator (JL Shepherd and Associates). UV was delivered at room temperature with a UV Stratalinker (Stratagene Cloning Systems).
Western analysis
Cell lysates were prepared and transferred onto membranes as previously described (Stewart et al., 1999a) . Membranes were incubated with mouse monoclonal antibodies against p53 (PAb1801), p21 (EA10) (Oncogene Research Products), and MDM2 (SMP14) (Santa Cruz Biotechnology); a rabbit polyclonal antibody against serine-15 phosphorylated p53 (New England Biolabs); and a goat polyclonal antibody against actin (I-19) (Santa Cruz Biotechnology). Primary antibodies were detected using goat a-mouse, goat a-rabbit, or rabbit a-goat horseradish peroxidase-conjugated secondary antibodies (Pierce) and enhanced chemiluminescence detection.
Northern analysis
mRNA was isolated from control and MTI-treated HCT116 cells, resolved by agarose gel electrophoresis, and transferred to nitrocellulose membrane (Gibco ± BRL) as previously described (Flatt et al., 2000) . Human MDM2, p21, and GADPH cDNAs were labeled with a-32 P-dCTP using Rediprime II (Amersham). After a 2 h prehybridization incubation in Express Hyb (Clontech Laboratories, Inc.) at 508C, membranes were incubated with 1610 6 c.p.m. of labeled cDNA per ml in Express Hyb at 508C overnight. Membranes were washed twice in 26SSC and 0.1% SDS (16SSC is 0.15 M NaCl plus 0.015 M sodium citrate) at 508C, followed by two washes in 0.26SSC and 0.1% SDS at 508C. The hybridized 32 P-labeled cDNAs were used to quantify mRNA levels on an Instant Imager (Packard Instrument) prior to autoradiography.
Two dimensional gel electrophoresis
For two dimensional (2D) gel analyses of endogenous p53 in HCT116 cells, 1 mg of protein lysate from control cells or 150 mg of protein lysate from treated cells were prepared in a ®nal volume of 600 ml of isoelectric focusing (IEF) sample buer (9.5 M urea (Pharmacia), 2% NP-40, 2% b-mercaptoethanol, 0.2% ampholytes pH 5-8 (Pharmacia), 0.001% bromophenol blue). For 2D analyses of p53 ectopically expressed in H1299 cells, 75 mg of protein lysate were prepared in a ®nal volume of 600 ml of IEF sample buer. A truncated form of recombinant human p53 (amino acids 1 ± 353) was incubated in each sample as an internal standard to permit alignment of p53 phospho-forms; the truncated human p53 was prepared as previously described (Szak and Pietenpol, 1999) . IEF was performed using the PROTEAN IEF system (Biorad) and 17 cm isoelectric strip gels pH 5-8 (Biorad). The isoelectric gels were passively rehydrated for 6 h in IEF sample buer containing the protein lysate prior to focusing for 60 000 volt-hours. After IEF, gels were incubated for 15 min in equilibration buer I (6M urea, 2% SDS, 0.375 M Tris (pH 8.8), 20% glycerol, 130 mM DTT) and 15 min in equilibration buer II (6M urea, 2% SDS, 0.375 M Tris (pH 8.8), 20% glycerol, 135 mM iodoacetamide (Aldrich Chemical Company, Inc.)) prior to separation by SDS ± PAGE.
Potato acid phosphatase treatment of protein lysates HCT116 protein lysates (150 mg) were incubated in 40 mM PIPES pH 6.0 (®nal volume 100 ml) for 10 min at 308C, followed by addition of 2.0 units of potato acid phosphatases (Boehringer Mannheim). The incubation was continued for 30 min at 308C. As a control for non-speci®c proteolytic degradation, protein lysates were also incubated in the absence of phosphatase under the same conditions. Phosphatase reactions were stopped by addition of Laemmli SDS ± PAGE or IEF sample buer.
Expression of p53 phosphorylation-site mutants
A panel of p53 phosphorylation-site mutants containing either alanine or aspartic acid substitutions for the indicated residues and the pCB6+ parental vector were a generous gift from Karen Vousden (National Cancer Institute, Frederick, MD, U.S.A.) (Ashcroft et al., 1999) . The p53 mutants include: serine-15 (S15A), threonine-18 (T18A and T18D), serine-20 (S20A), serine-37 (S37A), and a combination mutant with N-terminal and C-terminal phosphorylation sites modi®ed to alanine (S6A, S9A, S15A, T18A, S20A, S33A, S37A, S315A, S371A, S376A, S378A, S392A). The double p53 phosphorylation-site mutant S15A/T18A in the retroviral vector pLXSN was a generous gift of Peter Herrlich (Institut fuÈ r Genetik, Karlsruhe, Germany) (Blattner et al., 1999) . The cDNAs encoding wt p53 (KpnI ± BamHI fragment) and the S15A/T18A mutant protein (EcoRI fragment) were subcloned into the pCB6+ vector. All expression vectors were veri®ed by sequencing.
